

Claim 3 (original) The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 10, 11, 12, 16, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, and 33.

Claim 4 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Toll-like receptor 4.

Claim 12 (**original**) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (**original**) The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (**original**) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (**original**) A method of inhibiting the expression of Toll-like receptor 4 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Toll-like receptor 4 is inhibited.

A
Claim 16 (**original**) A method of treating an animal having a disease or condition associated with Toll-like receptor 4 comprising administering to said animal a therapeutically or prophylactically effective amount of compound of claim 1 so that expression of Toll-like receptor 4 is inhibited.

Claim 17 (**original**) The method of claim 16 wherein the condition is an inflammatory disorder.

Claim 18 (**original**) The method of claim 16 wherein the condition involves an immune response.

Claim 19 (**original**) The method of claim 18 wherein the immune response is Th1 response.

Claim 20 (**original**) A method of claim 18 wherein the immune response is a Th2 response.

Claim 21 (**new**) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a 5'-untranslated region (5'UTR) of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 22 (**new**) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a start region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 23 (**new**) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a coding region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 24 (**new**) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a stop region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 25 (**new**) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a 3'-untranslated region (3'UTR) of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 26 (**new**) The compound of claim 1, wherein said compound inhibits the expression of Toll-like receptor 4 by at least 50%.

Claim 27 (**new**) The compound of claim 1, wherein said compound inhibits the expression of Toll-like receptor 4 by at least 70%.
